Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Lenalidomide in Multiple Myeloma: NCT07334535 Clinical Landscape Report 2026
28 September 2026
NCT07334535 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Revlucabtagene Autoleucel in Relapse multiple myeloma: NCT07333430 Clinical Landscape Report 2026
28 September 2026
NCT07333430 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BMS-986453 in Multiple Myeloma: NCT07333261 Clinical Landscape Report 2026
28 September 2026
NCT07333261 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GT801 in Idiopathic Inflammatory Myopathies: NCT07333118 Clinical Landscape Report 2026
28 September 2026
NCT07333118 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
MC150 in Systemic Lupus Erythematosus: NCT07331467 Clinical Landscape Report 2026
28 September 2026
NCT07331467 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IBI-3003 in Relapse multiple myeloma: NCT07336472 Clinical Landscape Report 2026
28 September 2026
NCT07336472 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JY-232 in Multiple Myeloma: NCT07336823 Clinical Landscape Report 2026
28 September 2026
NCT07336823 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enpatoran in Lupus Erythematosus, Cutaneous: NCT07332481 Clinical Landscape Report 2026
28 September 2026
NCT07332481 clinical landscape for Lupus Erythematosus, Cutaneous: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride in Muscle Invasive Bladder Urothelial Carcinoma: NCT07332351 Clinical Landscape Report 2026
28 September 2026
NCT07332351 clinical landscape for Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
QLS12010 in Moderate Atopic Dermatitis: NCT07344051 Clinical Landscape Report 2026
28 September 2026
NCT07344051 clinical landscape for Moderate Atopic Dermatitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Recurrent Multiple Myeloma: NCT07340853 Clinical Landscape Report 2026
28 September 2026
NCT07340853 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine Hydrochloride/Docetaxel in Urothelial Carcinoma of the Urinary Bladder: NCT07342517 Clinical Landscape Report 2026
28 September 2026
NCT07342517 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…